1. Medtech Insight
  2. >>Business
  3. >>Strategy

Novocure Transforms Patient Support System During Pandemic

 
• By Reed Miller

The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.

Soft and blurry image:Medical image MRI Brain showing There is diameter cystic mass or tumor at Left frontal lobe Glioblastoma at Lt frontal lobe with metastasis, brain metastases.
• Source: shutterstock.com

NovoCure Limited is adapting to the challenges created by the pandemic supporting patients who use its Tumor Treating Fields (TTF) devices to treat brain and lung cancer.

The company markets the Optune TTF device to treat glioblastomas, an aggressive type of brain tumor. It also markets the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

BD Names First CRO To Drive Commercial Overhaul As ’New BD‘ Strategy Builds Toward 2026 Launch

 
• By Shubham Singh

As BD refines its commercial model, it has also brought leadership transition to its finance organization. The company recently announced that executive vice president and chief financial officer Chris DelOrefice will depart BD effective Dec. 5.

Stryker Eyes Double-Digit Inari Growth Through Early 2026, With Global Expansion To Follow

 
• By Shubham Singh

Record Mako installations in the third quarter fueled growth across Stryker’s orthopedics portfolio, supporting higher revenue in the “Ortho Other” category. Executives said new product launches and software upgrades are broadening clinical applications.

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Philips Ramps Up US Production, Seeks To Swiftly Move On From New FDA Warning Letter

 
• By Shubham Singh

Philips puts its latest “disappointing” warning letter into context, while announcing progress in regulatory performance, expanded US production and tariff resilience plans

More from Business

Deals Shaping The Medtech And Diagnostics Industries, October 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during October 2025. Data courtesy of Biomedtracker.

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Makary And Oz Tout Successes At Their Respective Agencies, Say They Are Breaking Down Walls

 
• By Brian Bossetta

Nearly one year into leading their agencies, US FDA Commission Marty Makary and CMS Administrator Mehmet Oz took to the stage together at the Milken Institute’s Future of Health Summit 2025 to highlight what they see as progress and lay out plans for the road ahead.